Michael G Brattain
Overview
Explore the profile of Michael G Brattain including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
66
Citations
1702
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ammanamanchi S, Tillekeratne M, Ko T, Brattain M
Cancer Res
. 2021 Sep;
79(5):1016.
PMID: 34465568
No abstract available.
2.
Leiphrakpam P, Lazenby A, Smith L, Brattain M, Are C
J Surg Oncol
. 2021 Mar;
123(8):1764-1772.
PMID: 33765336
Objectives: To evaluate the relationship between stathmin expression and clinical outcome in colorectal cancer (CRC). Background: Stathmin is a phosphoprotein involved in the regulation of microtubule dynamics and integration of...
3.
Leiphrakpam P, Lazenby A, Smith L, Brattain M, Black J, Wang J, et al.
J Surg Oncol
. 2020 Nov;
123(1):42-51.
PMID: 33179291
Objectives: To evaluate the relationship between phosphatase of regenerating liver 3 (PRL3) expression and clinical outcome in colorectal cancer (CRC). Background: PRL3, a protein tyrosine phosphatase functions as one of...
4.
Robb C, Kour S, Contreras J, Agarwal E, Barger C, Rana S, et al.
Oncotarget
. 2020 Jul;
11(25):2462-2463.
PMID: 32637035
[This corrects the article DOI: 10.18632/oncotarget.23749.].
5.
Leiphrakpam P, Lazenby A, Chowdhury S, Smith L, Mathiesen M, Brattain M, et al.
J Surg Oncol
. 2019 Dec;
121(3):547-560.
PMID: 31867736
Background: Na /H exchanger regulatory factor 1 (NHERF1) has been implicated in the tumorigenesis of several cancer types and is a potential therapeutic target. The current study evaluated the relationship...
6.
Laschanzky R, Humphrey L, Ma J, Smith L, Enke T, Shukla S, et al.
Cancers (Basel)
. 2019 Sep;
11(9).
PMID: 31500290
Pancreatic ductal adenocarcinoma (PDAC) has a five-year survival rate of <10% due in part to a lack of effective therapies. Pan-histone deacetylase (HDAC) inhibitors have shown preclinical efficacy against PDAC...
7.
Leiphrakpam P, Brattain M, Black J, Wang J
J Biol Chem
. 2018 Mar;
293(21):8242-8254.
PMID: 29599290
Aberrant cell survival plays a critical role in cancer progression and metastasis. We have previously shown that ezrin, a cAMP-dependent protein kinase A-anchoring protein (AKAP), is up-regulated in colorectal cancer...
8.
Robb C, Kour S, Contreras J, Agarwal E, Barger C, Rana S, et al.
Oncotarget
. 2018 Feb;
9(4):5216-5232.
PMID: 29435174
Colorectal cancer (CRC) remains one of the leading causes of cancer related deaths in the United States. Currently, there are limited therapeutic options for patients suffering from CRC, none of...
9.
Bailey K, Agarwal E, Chowdhury S, Luo J, Brattain M, Black J, et al.
PLoS One
. 2017 Apr;
12(4):e0176096.
PMID: 28414818
In this study, we have uncovered a novel crosstalk between TGFβ and IGF-1R signaling pathways. We show for the first time that expression and activation of IRS-1, an IGF-1R adaptor...
10.
Rajput A, Agarwal E, Leiphrakpam P, Brattain M, Chowdhury S
ISRN Hepatol
. 2016 Jun;
2013:206875.
PMID: 27340651
Metastases are largely responsible for cancer deaths in solid tumors due to the lack of effective therapies against disseminated disease, and there is an urgent need to fill this gap....